Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Reck

Showing results (371-380 of 438) with videos related to

Pageof 44
Sort By:
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC TrialCorinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainNaoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Cell Metabolism|June 3, 2026
IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibitionSiavash Mansouri, Golnaz Hesami, Anoop Ambikan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 44

Showing results (371-380 of 438) with videos related to

Sort By:
Pageof 44
Lung Cancer (Amsterdam, Netherlands)|September 22, 2024
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension studyMartin Reck, Rafal Dziadziuszko, Shunichi Sugawara, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 24, 2021
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1Martin Reck, Tudor-Eliade Ciuleanu, Jong-Seok Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2021
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC TrialCorinne Faivre-Finn, David Vicente, Takayasu Kurata, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 9, 2021
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or BrainNaoyuki Nogami, Fabrice Barlesi, Mark A Socinski, et al.
Lancet (London, England)|July 9, 2023
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled studySiow Ming Lee, Christian Schulz, Kumar Prabhash, et al.
Future Oncology (London, England)|May 20, 2025
A plain language summary of atezolizumab compared with single-agent chemotherapy in participants with non-small cell lung cancer who should not receive platinum-based chemotherapy (the IPSOS study)Siow Ming Lee, Christian Schulz, Anne-Marie Baird, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2022
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) surveySara Pilotto, Alice Avancini, Jessica Menis, et al.
Journal for Immunotherapy of Cancer|February 12, 2024
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trialDavid P Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, et al.
Cell Metabolism|June 3, 2026
IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibitionSiavash Mansouri, Golnaz Hesami, Anoop Ambikan, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2023
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomesMartin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, et al.
Pageof 44